Project Details
Description
One in every 11 children in the UK has asthma. When asthma is well managed, children can lead full and active lives. Sadly, not all asthma is well controlled. Many children with asthma experience residual and troublesome symptoms that impair their quality of life despite taking their asthma medication regularly. Children with asthma cough, wheeze and have difficulty breathing. Symptoms can impact school attendance, participation in playground games and sports and can lead to hospital admission.
Effective medicines are available, however, responses to these medicines are currently unpredictable. This project focuses on an asthma controller medicine called salmeterol. According to reports, tens of thousands of children may be taking this medicine in the UK, but evidence suggests it might not work for around one in seven of them. Our research group previously found that there are certain gene variations which are linked to poor asthma control in children and young people.
The personalised medicine for asthma control (PACT) study is a collaboration between physicians and researchers in Scotland and England funded by Action Medical Research and The Henry Smith Charity. We are investigating whether a new, tailored approach to treatment, taking a child’s genetic make-up into account, can improve quality of life and result in better asthma control. Treatment that is tailored in this way is often called ‘personalised medicine’.
The aim of the research project is to determine whether prescribing children with inadequately controlled asthma further drug therapy on the basis of their Arginine16 (Arg16) genetic status improves asthma quality of life and control, compared to prescribing using the current method of doctor or nurse choice informed by British Thoracic Society (BTS) guidelines. A simple and inexpensive saliva test can provide the information needed to guide decision making.
Effective medicines are available, however, responses to these medicines are currently unpredictable. This project focuses on an asthma controller medicine called salmeterol. According to reports, tens of thousands of children may be taking this medicine in the UK, but evidence suggests it might not work for around one in seven of them. Our research group previously found that there are certain gene variations which are linked to poor asthma control in children and young people.
The personalised medicine for asthma control (PACT) study is a collaboration between physicians and researchers in Scotland and England funded by Action Medical Research and The Henry Smith Charity. We are investigating whether a new, tailored approach to treatment, taking a child’s genetic make-up into account, can improve quality of life and result in better asthma control. Treatment that is tailored in this way is often called ‘personalised medicine’.
The aim of the research project is to determine whether prescribing children with inadequately controlled asthma further drug therapy on the basis of their Arginine16 (Arg16) genetic status improves asthma quality of life and control, compared to prescribing using the current method of doctor or nurse choice informed by British Thoracic Society (BTS) guidelines. A simple and inexpensive saliva test can provide the information needed to guide decision making.
Key findings
First trial of personalised care for children with asthma suggests benefits
The trial compares patients treated according to existing guidelines with those treated by ‘personalised medicine’ and is the first of its kind in children and teenagers.
Researchers say that more work is needed, but their findings hint that children’s asthma symptoms could be better controlled with personalised treatments.
The study was presented at the virtual European Respiratory Society International Congress, by Dr Tom Ruffles, honorary consultant in paediatric respiratory medicine, who worked with the study team led by Professor Somnath Mukhopadhyay, Chair in Paediatrics. Both are based at the Royal Alexandra Children’s Hospital, and BSMS, UK. The trial was conducted and managed by the Tayside Clinical Trials Unit at the University of Dundee, UK.
Dr Ruffles told the conference: “Asthma is a common condition in children that causes coughing, wheezing and difficulty breathing. In the UK, for example, asthma affects one in 11 children and every 18 minutes a child is admitted to hospital because of their asthma.
“We have a number of medicines that are generally effective in treating children with asthma, but they don’t work equally well for all children. We think that genetic differences could have an effect on whether these medicines work, and that’s what we wanted to examine in this study.”
The research involved 241 young people aged between 12 and 18 who were all being treated for asthma by their GPs. The children were randomly assigned either to receive treatment according to existing guidelines, or to receive treatment according to particular genetic differences (their genotype), an approach known as personalised medicine.
Treatment according to genotype meant the children were asked to give a sample of cells scraped from the inside of their cheeks. These samples were tested for different versions of a particular gene, using a test that costs less than €20.
The researchers were testing for a small difference in the gene that contains instructions for making the beta-2 receptor and they were looking for children who had either with one copy of the altered gene or with two copies of the altered gene. The beta-2 receptor is the molecule that is targeted by asthma treatments. Therefore, researchers believe that different versions of the gene for making this receptor can influence how well treatments work.
Previous research suggests that the majority of children with asthma will benefit from standard treatment with an asthma preventer called salmeterol in addition to their regular steroid inhaler. However, around one in seven children have a small genetic difference that means using this medication could actually result in these children having more asthma symptoms.
In this trial, children in the personalised medicine group who had this genetic difference were treated with an alternative asthma medicine called montelukast.
Researchers followed the children for a year to monitor their quality of life, with a score between one and seven according to how their symptoms were, whether their normal activities were limited by their asthma and how their asthma made them feel.
They compared the average score of the group of children who had their medication decided on the basis of their genetics with the average score of children who were treated according to current practice that does not involve any genetic testing, and found only a small improvement of 0.16 with those who received personalised care.
However, when the researchers looked specifically at the children who were found to have two copies of the altered beta-2 receptor gene, they found a greater benefit, with children experiencing an average 0.42 improvement in their quality of life score. The researchers say this would translate to a noticeably better quality of life for the children with two altered gene copies.
Professor Mukhopadhyay said: “These results are very promising because they show, for the first time, that it could be beneficial to test for certain genetic differences in children with asthma and select medication according to those differences.
“In this study, we saw only a modest effect, but this may be partly because the children’s asthma was generally very well controlled and only a few children experienced any serious symptoms during the 12-month period. Larger trials, with a focus on those with poorer asthma control, may help us determine the true benefit for children of prescribing in this way.”
Professor Chris Brightling, from the University of Leicester, UK, is European Respiratory Society Science Council Chair and was not involved in the research. He said: “This approach of ‘personalised care’ for both children and adults with asthma is an important goal for respiratory research.
“In this study, researchers used genetic information that we know is linked to how well patients respond to some inhaler treatments. They found that making use of this genetic information improved the outcome for children with asthma.”
The trial compares patients treated according to existing guidelines with those treated by ‘personalised medicine’ and is the first of its kind in children and teenagers.
Researchers say that more work is needed, but their findings hint that children’s asthma symptoms could be better controlled with personalised treatments.
The study was presented at the virtual European Respiratory Society International Congress, by Dr Tom Ruffles, honorary consultant in paediatric respiratory medicine, who worked with the study team led by Professor Somnath Mukhopadhyay, Chair in Paediatrics. Both are based at the Royal Alexandra Children’s Hospital, and BSMS, UK. The trial was conducted and managed by the Tayside Clinical Trials Unit at the University of Dundee, UK.
Dr Ruffles told the conference: “Asthma is a common condition in children that causes coughing, wheezing and difficulty breathing. In the UK, for example, asthma affects one in 11 children and every 18 minutes a child is admitted to hospital because of their asthma.
“We have a number of medicines that are generally effective in treating children with asthma, but they don’t work equally well for all children. We think that genetic differences could have an effect on whether these medicines work, and that’s what we wanted to examine in this study.”
The research involved 241 young people aged between 12 and 18 who were all being treated for asthma by their GPs. The children were randomly assigned either to receive treatment according to existing guidelines, or to receive treatment according to particular genetic differences (their genotype), an approach known as personalised medicine.
Treatment according to genotype meant the children were asked to give a sample of cells scraped from the inside of their cheeks. These samples were tested for different versions of a particular gene, using a test that costs less than €20.
The researchers were testing for a small difference in the gene that contains instructions for making the beta-2 receptor and they were looking for children who had either with one copy of the altered gene or with two copies of the altered gene. The beta-2 receptor is the molecule that is targeted by asthma treatments. Therefore, researchers believe that different versions of the gene for making this receptor can influence how well treatments work.
Previous research suggests that the majority of children with asthma will benefit from standard treatment with an asthma preventer called salmeterol in addition to their regular steroid inhaler. However, around one in seven children have a small genetic difference that means using this medication could actually result in these children having more asthma symptoms.
In this trial, children in the personalised medicine group who had this genetic difference were treated with an alternative asthma medicine called montelukast.
Researchers followed the children for a year to monitor their quality of life, with a score between one and seven according to how their symptoms were, whether their normal activities were limited by their asthma and how their asthma made them feel.
They compared the average score of the group of children who had their medication decided on the basis of their genetics with the average score of children who were treated according to current practice that does not involve any genetic testing, and found only a small improvement of 0.16 with those who received personalised care.
However, when the researchers looked specifically at the children who were found to have two copies of the altered beta-2 receptor gene, they found a greater benefit, with children experiencing an average 0.42 improvement in their quality of life score. The researchers say this would translate to a noticeably better quality of life for the children with two altered gene copies.
Professor Mukhopadhyay said: “These results are very promising because they show, for the first time, that it could be beneficial to test for certain genetic differences in children with asthma and select medication according to those differences.
“In this study, we saw only a modest effect, but this may be partly because the children’s asthma was generally very well controlled and only a few children experienced any serious symptoms during the 12-month period. Larger trials, with a focus on those with poorer asthma control, may help us determine the true benefit for children of prescribing in this way.”
Professor Chris Brightling, from the University of Leicester, UK, is European Respiratory Society Science Council Chair and was not involved in the research. He said: “This approach of ‘personalised care’ for both children and adults with asthma is an important goal for respiratory research.
“In this study, researchers used genetic information that we know is linked to how well patients respond to some inhaler treatments. They found that making use of this genetic information improved the outcome for children with asthma.”
| Acronym | PACT |
|---|---|
| Status | Finished |
| Effective start/end date | 1/01/15 → 30/09/17 |
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.